ReAct Europe, Uppsala University, decided in 2013 to participate in DRIVE-AB* because we believed this project was an opportunity to draw on the experience of a broad set of stakeholders to deliver recommendations for truly transformative innovation models that would ensure both equitable access to and conservation of new antibiotics.
Important research by academic partners has been carried out during the course of DRIVE-AB, which will hopefully contribute to the ongoing debate on novel models for innovation, access and conservation of new antibiotics.
However, over the course of the project, the management, whereby each work package was co-led by industry and academic partners, led to unresolved problems of conflict of interest in shaping policy recommendations. The lack of clearly established processes to guide decision-making, lessened our confidence in the ability of the project to present multistakeholder recommendations where possible, as well as being transparent about areas of dissent.
The culmination was a recent commentary submitted for publication to the Lancet Infectious Diseases on behalf of the DRIVE-AB Steering Committee that contained preliminary recommendations that were not agreed upon nor supported by the full group; however, this fact was not reflected in the commentary.
ReAct cannot stand behind a process where recommendations ignoring key disagreements in the group are presented with the aim to be perceived as multistakeholder recommendations, and has therefore decided to withdraw from DRIVE-AB.
For any further enquiries please contact:
Helle Aagaard, e-mail: email@example.com, Phone: +46 18 471 66 80
ABOUT DRIVE AB
*DRIVE-AB is a research project under The Innovative Medicines Initiative (IMI) – a public-private joint undertaking between the European Commission and the European Pharmaceutical Industry Association (EFPIA).
The overall budget of the DRIVEAB is €10,8M out of which the European Commission provides €6,3M and EFPIA partners provide approximately €3M in in-kind contributions. DRIVEAB has 16 public and 7 private partners. In order to balance the private and public interest in the project representatives from both groups have co-led the various work streams.
More from "2017"
- Resistance to last-line antibiotics
- Essential Diagnostics List (EDL) to be developed
- Media workshop in Ecuador: a success
- ReAct withdraws from IMI project DRIVE-AB
- Microbes – friend, foe or both?
- ReAct Asia Pacific hosts workshop on antimicrobial resistance in the farm sector
- Successful antimicrobial resistance media training in Nairobi, Kenya
- Mother Earth, One Health – International Encounter in Argentina
- Key take-aways from the World Health Assembly 2017 on antimicrobial resistance
- National action plans and global AMR framework on the agenda as 70th World Health Assembly kicks off next week
- ReAct co-hosts side event during World Health Assembly
- ReAct supports countries in the development of National Action Plans on AMR
- Lack of access to old antibiotics drives antibiotic resistance development and impairs patient outcomes
- Hand hygiene saves lives
- The Swedish Government awards Reward Medal to Professor Otto Cars
- Presentation of the Alforja Educativa Validation Project enthuses students
- New antibiotics in the news
- Free online course: Antibiotic Resistance: the Silent Tsunami
- Tell Our Bac-Stories!
- India’s link between tuberculosis and antibiotic resistance
- Environmental effects of antibiotics in sewage
- Professor Larsson on India’s National Action Plan on AMR and emissions from antibiotics production
- India’s new National Action Plan on Antimicrobial Resistance
- Professor Otto Cars to serve as Expert in UN Inter-Agency Coordination Group on Antimicrobial Resistance
- Johns Hopkins Bloomberg School of Public Health is looking for a Research Associate
- Could the use of Antimicrobial Peptides create resistance to ourselves?
- Boston Consulting Group report shies away from addressing affordable access and stewardship
- WHO Releases Priority Pathogens List
- Antibiotic Smart Use project nominated for global UN Award
- European Commission diagnostic prize winner announced
- Recap of WHO 140th Executive Board meeting
- New collaboration on strategies for tackling antibiotic resistance